Entrada Therapeutics, Inc. (TRDA) Social Stream



Entrada Therapeutics, Inc. (TRDA): $14.35

0.59 (+4.29%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add TRDA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#21 of 363

in industry

ENTRADA THERAPEUTICS INC (TRDA) Price Targets From Analysts

Use the tables below to see what analysts covering ENTRADA THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-05-24 3 $10 $10 $10 $16.13 -38%
2022-08-16 4 $13 $13 $13 $16.13 -19.4%
2022-11-08 4 $18 $18 $18 $16.13 11.59%
2023-11-08 3 $25 $18 $21.5 $16.13 33.29%
2023-11-27 4 $20 $18 $19 $16.13 17.79%
NA 2 $NA $NA $NA $16.13 NA%

The Trend in the Analyst Price Target


TRDA's average price target has moved down $2.5 over the prior 34 weeks.

TRDA reports an average of 45.73% for its upside potential over the past 34 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-08-02 3 25 18 21.5 14.89 44.39%
2023-08-09 3 25 18 21.5 15.31 40.43%
2023-09-30 3 25 18 21.5 15.80 36.08%
2023-11-08 3 25 18 21.5 16.87 27.45%
2023-11-27 3 20 18 19.0 12.50 52%

TRDA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.5 3 0 1 0 0 4

The Trend in the Broker Recommendations


TRDA's average broker recommendation rating improved by 0 over the prior 61 days.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for TRDA as an investment opportunity.

  • In the context of all US stocks, ENTRADA THERAPEUTICS INC's number of analysts covering the stock is higher than 89.73% of them.
  • TRDA has a lower variance in analysts' estimates than 70.9% of Pharmaceutical Products stocks.
  • TRDA has a higher upside potential (average analyst target price relative to current price) than 149.59% of Pharmaceutical Products stocks.
  • To contextualize these metrics, consider that out of Healthcare stocks, ENTRADA THERAPEUTICS INC's average analyst price target is higher than 261.47% of them.

In the Pharmaceutical Products industry, LIAN, TSVT, and VAXX are the three stocks most similar to ENTRADA THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.

Is TRDA a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!